Compare ADMA Biologics Inc (ADMA) vs Garmin Ltd. (GRMN) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
ADMA Biologics Inc vs Garmin Ltd. — how do they compare? ADMA Biologics Inc trades at $9.22 (market cap $2.13B), while Garmin Ltd. trades at $243.53 (market cap $47.96B). The key difference: Garmin Ltd. is far larger — about 22.5× ADMA Biologics Inc's market cap, and Garmin Ltd. pays a 1.69% dividend while ADMA Biologics Inc pays none. Which is the better fit depends on your goals.
| ADMA | GRMN | |
|---|---|---|
Market Cap | $2.13B | $47.96B |
Sector | Health | Technology |
52-Week High | $20.38 | $267.52 |
52-Week Low | $7.60 | $187.10 |
Enterprise Value | $2.20B | $45.43B |
Dividend Yield | — | 1.69% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ADMA trades at $9.16, up 2.35% today, with a bullish technical signal from moving averages and oscillators. The company reported strong profitability with a 32.43% net income margin and 43.3% ROE for 2025, though recent EPS results were mixed. Analyst consensus is strongly bullish with an $19.00 price target, but multiple class action lawsuits filed in July 2026 alleging securities fraud create significant near-term uncertainty.
The stock offers substantial upside to analyst targets if legal challenges are resolved favorably, supported by robust fundamentals and projected cash flow growth. Primary risks include the outcome of ongoing litigation and potential reputational damage. Investors should weigh strong financial performance against elevated legal and sentiment risks before establishing a position.
Garmin (GRMN) trades at $248.68, up 3.63% today, reflecting strong momentum near its recent highs. The stock exhibits a bullish technical trend, supported by robust fundamentals including a 23.26% net income margin and consistent revenue growth from $4.9B in 2022 to $7.25B in 2025. Recent product launches like LiveScope 2 and positive earnings beats in Q4 2025 and Q1 2026 underscore operational strength.
The outlook remains favorable with a consensus price target of $282.67, though risks include competitive pressures and market volatility. Investment appeal centers on sustained profitability and innovation, but investors should weigh high valuation multiples against growth sustainability.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About ADMA Biologics Inc
ADMA Biologics is a biopharmaceutical company specializing in plasma-derived therapies for immunodeficient patients. Key products like ASCENIV and BIVIGAM treat primary humoral immunodeficiency and help prevent infectious diseases.
Read more on ADMA →About Garmin Ltd.
Garmin produces GPS-enabled hardware and software for five verticals: fitness, outdoors, auto, aviation, and marine. The company relies on licensing mapping data to enable its hardware specialized for often niche activities like scuba diving or sailing. Garmin operates in 100 countries and sells its products via distributors as well as relationships with original equipment manufacturers.
Read more on GRMN →
